The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients.

Objectives: The aim of the study was to evaluate the role of F-fluorodeoxyglucose ((18)F-FDG) PET/computed tomography (CT) in the early postoperative staging of breast cancer and to document (18)F-FDG PET/CT-based stage alterations and any subsequent impact on management.

Materials And Methods: Between January 2009 and June 2012, PET/CT images of patients with histopathologically proven breast cancer who underwent surgery with no previous chemotherapy or radiotherapy were retrospectively reviewed. Any stage alteration due to a change in nodal or metastatic status on PET/CT was noted.

The clinical value of incidental 18F-fluorodeoxyglucose-avid foci detected on positron emission tomography/computed tomography.

Objective: This study was performed to show the malignant potential and clinical value of incidental focal 18F-fluorodeoxyglucose (18F-FDG) uptake on positron emission tomography/computed tomography (PET/CT) with the confirmation of histopathologic findings or with a series of consequent correlative imaging methods.

Methods: A total of 2370 18F-FDG-PET/CT studies performed over a 16-month period in patients with various malignant diseases were retrospectively reviewed. Unexpected PET foci that were in an unusual site for metastatic spread of known malignancy and not considered to be physiologic uptake were evaluated by histopathologic findings or follow-up with correlative imaging methods for a period of 1 year or longer.

Contribution of 99mTc-sestamibi infusion SPECT to the characterization of fixed perfusion defects.

In patients with coronary artery disease, the distinction between scar and viable myocardium by means of myocardial perfusion imaging (MPI) sometimes can be difficult because of the equivocal meaning of fixed perfusion defects. In this study we examined whether addition of a 99mTc-sestamibi infusion study to the standard MPI could provide extra information regarding the fixed defects. Thirty-seven patients underwent standard MPI and an extra SPECT study in which 99mTc-sestamibi was given as a prolonged constant infusion.